{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:17:18Z","timestamp":1761902238274,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013412","name":"Sanofi Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.msard.2023.104909","type":"journal-article","created":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T03:52:06Z","timestamp":1689997926000},"page":"104909","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Real-world persistence to first-line DMTs in relapsing-remitting multiple sclerosis"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7682-6464","authenticated-orcid":false,"given":"Clara","family":"L\u00f3pez-Caneda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"P\u00e9rez-Haro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9sar","family":"S\u00e1nchez-Franco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"\u00c1lvarez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Aguado-Valc\u00e1rcel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Marcos-Bobillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e9s","family":"Gonz\u00e1lez-Suarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.msard.2023.104909_bib0001","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.neurol.2018.03.012","article-title":"First-line therapy in relapsing remitting multiple sclerosis","volume":"174","author":"Biotti","year":"2018","journal-title":"Rev. Neurol."},{"issue":"21","key":"10.1016\/j.msard.2023.104909_bib0002","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1212\/WNL.0000000000005561","article-title":"Preapproval and postapproval evidence on drugs for multiple sclerosis","volume":"90","author":"Gerardi","year":"2018","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2023.104909_bib0003","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.msard.2023.104909_bib0004","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1212\/WNL.0000000000002441","article-title":"Long-term safety and efficacy of teriflunomide","volume":"86","author":"O'Connor","year":"2016","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2023.104909_bib0005","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1007\/s00415-014-7412-x","article-title":"Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study","volume":"261","author":"Arnold","year":"2014","journal-title":"J. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2023.104909_bib0006","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1212\/WNL.0000000000001360","article-title":"Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study","volume":"84","author":"Miller","year":"2015","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2023.104909_bib0007","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3111\/13696998.2015.1134546","article-title":"The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis","volume":"19","author":"Thomas","year":"2016","journal-title":"J. Med. Econ."},{"issue":"5","key":"10.1016\/j.msard.2023.104909_bib0008","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1007\/s00415-018-8831-x","article-title":"A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study","volume":"265","author":"Lanzillo","year":"2018","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2023.104909_bib0009","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s13311-020-01001-6","article-title":"Injectable versus oral first-line disease-modifying therapies: results from the Italian MS register","volume":"18","author":"D'Amico","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"6","key":"10.1016\/j.msard.2023.104909_bib0010","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/ane.13301","article-title":"Medication adherence\/persistence among patients with active multiple sclerosis in Finland","volume":"142","author":"Lahdenper\u00e4","year":"2020","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2023.104909_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102521","article-title":"An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014 to 2017","volume":"46","author":"Vermersch","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"8","key":"10.1016\/j.msard.2023.104909_bib0012","first-page":"844","article-title":"Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year","volume":"23","author":"Johnson","year":"2017","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"3","key":"10.1016\/j.msard.2023.104909_bib0013","doi-asserted-by":"crossref","first-page":"567","DOI":"10.4103\/1673-5374.320985","article-title":"Injectable versus oral first-line multiple sclerosis therapies: knows and unknowns from observational studies","volume":"17","author":"D'Amico","year":"2022","journal-title":"Neural Regen. Res."},{"issue":"1","key":"10.1016\/j.msard.2023.104909_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210417","article-title":"A retrospective claims analysis: compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies. Ramagopalan SV","volume":"14","author":"Duquette","year":"2019","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.msard.2023.104909_bib0015","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s40120-022-00404-1","article-title":"Persistence, adherence, and switching to higher-cost therapy in patients with multiple sclerosis initiating oral disease-modifying therapies: a retrospective real-world study","volume":"11","author":"Araujo","year":"2022","journal-title":"Neurol. Ther."},{"issue":"4","key":"10.1016\/j.msard.2023.104909_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123824","article-title":"Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study. Linker RA","volume":"10","author":"Zhornitsky","year":"2015","journal-title":"PLoS One"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823004108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823004108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:11:34Z","timestamp":1761901894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823004108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":16,"alternative-id":["S2211034823004108"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104909","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world persistence to first-line DMTs in relapsing-remitting multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104909","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104909"}}